ActiGraph, the provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will allow both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.
ActiGraph’s wearable activity monitoring sensors provide pharma companies with levels of continuous, high-resolution physiologic data. The collection and accurate analysis of biometric data streams is vital in today’s clinical research and helps to accelerate study enrollment and patient engagement.
VivoSense analyzes data from any biometric sensor or combination of sensors to integrate, clean, analyze, and derive new biomarkers. The large physiological data-sets generated by these sensors help to monitor health and understand the effects of new medicines and therapies in development.
"Providing context to collected wearable sensor data empowers our clients to make better sense of the data and investigate novel disease endpoints,” said Dudley Tabakin, CEO and Co-founder of VivoSense. "Combining ActiGraph’s world-leading activity and sleep monitoring with other physiological measures, cleaned and analyzed by VivoSense, will provide context to all clinical trials measures."
For more information, visit www.actigraphcorp.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.